Characteristic | n |
Patient population | |
Female | 89 (98) |
Premenopausal (women only, n = 89) | 15 (17) |
Weight | |
Normal (body mass index ≤ 25) | 30 (33) |
Overweight | 32 (35) |
Obese (body mass index > 30) | 29 (32) |
Primary tumor immunohistochemistry and histology | |
ER+ | 90 (99) |
Progesterone receptor–positive (n = 88) | 74 (84) |
HER2/neu–positive | 12 (13) |
Histology | |
Ductal | 67 (73) |
Lobular | 18 (20) |
Ductal and lobular | 6 (7) |
Breast cancer and treatment history | |
Advanced disease | 86 (95) |
Chemotherapy for metastatic breast cancer (n = 82)* | 21 (26) |
Endocrine therapy for metastatic breast cancer (n = 82)* | 38 (46) |
Radiation therapy for metastatic breast cancer (n = 82)* | 28 (34) |
Aromatase inhibitor therapy at time of scan (n = 90) | 55 (61) |
Tumor characteristics† | |
Bone lesions present | 67 (74) |
Soft-tissue lesions present | 54 (59) |
Both bone and soft-tissue lesions present | 31 (34) |
Endocrine therapy after 18F-fluoroestradiol PET | |
Tamoxifen | 6 (7) |
Aromatase inhibitor | 60 (66) |
Aromatase inhibitor and fulvestrant | 18 (20) |
Other or unknown‡ | 7 (7) |
* Patients without advanced disease (n = 5) excluded, history unknown for n = 4.
† Lesions in 18F-fluoroestradiol PET analysis.
‡ Fulvestrant alone, leuprolide acetate, diethylstilbestrol, 4 unknown.
Data in parentheses are percentages. Mean age (±SD) of patient population was 56 ± 11 y (median, 55 y; range, 28–79 y). Mean years since breast cancer diagnosis was 7 ± 6 y (median, 5 y; range, 0–31 y). Mean years since first cancer recurrence (advanced disease only, n = 86) was 2 ± 3 (median, 0.3 y; range, 0–17 y). Mean number of lesions was 5.6 ± 4.0 (median, 4; range, 1–16).